Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 23 02 2021
accepted: 25 06 2021
entrez: 12 7 2021
pubmed: 13 7 2021
medline: 17 11 2021
Statut: epublish

Résumé

Ferritin is the major iron storage protein and an acute phase reactant. Hyperferritinemia is frequently seen in the critically ill where it has been hypothesized that not only underlying conditions but also factors such as transfusions, hemodialysis and extracorporeal life support (ECLS) lead to hyperferritinemia. This study aims to investigate the influence of transfusions, hemodialysis, and ECLS on hyperferritinemia in a multidisciplinary ICU cohort. This is a post-hoc analysis of a retrospective observational study including patients aged ≥ 18 years who were admitted to at least one adult ICU between January 2006 and August 2018 with hyperferritinemia ≥ 500 μg/L and of ≥ 14 days between two ICU ferritin measurements. Patients with hemophagocytic lymphohistiocytosis (HLH) were excluded. To identify the influence of transfusions, hemodialysis, and ECLS on ferritin change, multivariable linear regression analysis with ferritin change between two measurements as dependent variable was performed. A total of 268 patients was analyzed. Median duration between measurements was 36 days (22-57). Over all patients, ferritin significantly increased between the first and last measurement (p = 0.006). Multivariable linear regression analysis showed no effect of transfusions, hemodialysis, or ECLS on ferritin change. Changes in aspartate aminotransferase (ASAT) and sequential organ failure assessment (SOFA) score were identified as influencing factors on ferritin change [unstandardized regression coefficient (B) = 2.6; (95% confidence interval (CI) 1.9, 3.3); p < 0.001 and B = 376.5; (95% CI 113.8, 639.1); p = 0.005, respectively]. Using the same model for subgroups of SOFA score, we found SOFA platelet count to be associated with ferritin change [B = 1729.3; (95% CI 466.8, 2991.9); p = 0.007]. No association of ferritin change and in-hospital mortality was seen in multivariable analysis. The present study demonstrates that transfusions, hemodialysis, and ECLS had no influence on ferritin increases in critically ill patients. Hyperferritinemia appears to be less the result of iatrogenic influences in the ICU thereby underscoring its unskewed diagnostic value. The study was registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016.

Sections du résumé

BACKGROUND
Ferritin is the major iron storage protein and an acute phase reactant. Hyperferritinemia is frequently seen in the critically ill where it has been hypothesized that not only underlying conditions but also factors such as transfusions, hemodialysis and extracorporeal life support (ECLS) lead to hyperferritinemia. This study aims to investigate the influence of transfusions, hemodialysis, and ECLS on hyperferritinemia in a multidisciplinary ICU cohort.
METHODS
This is a post-hoc analysis of a retrospective observational study including patients aged ≥ 18 years who were admitted to at least one adult ICU between January 2006 and August 2018 with hyperferritinemia ≥ 500 μg/L and of ≥ 14 days between two ICU ferritin measurements. Patients with hemophagocytic lymphohistiocytosis (HLH) were excluded. To identify the influence of transfusions, hemodialysis, and ECLS on ferritin change, multivariable linear regression analysis with ferritin change between two measurements as dependent variable was performed.
RESULTS
A total of 268 patients was analyzed. Median duration between measurements was 36 days (22-57). Over all patients, ferritin significantly increased between the first and last measurement (p = 0.006). Multivariable linear regression analysis showed no effect of transfusions, hemodialysis, or ECLS on ferritin change. Changes in aspartate aminotransferase (ASAT) and sequential organ failure assessment (SOFA) score were identified as influencing factors on ferritin change [unstandardized regression coefficient (B) = 2.6; (95% confidence interval (CI) 1.9, 3.3); p < 0.001 and B = 376.5; (95% CI 113.8, 639.1); p = 0.005, respectively]. Using the same model for subgroups of SOFA score, we found SOFA platelet count to be associated with ferritin change [B = 1729.3; (95% CI 466.8, 2991.9); p = 0.007]. No association of ferritin change and in-hospital mortality was seen in multivariable analysis.
CONCLUSIONS
The present study demonstrates that transfusions, hemodialysis, and ECLS had no influence on ferritin increases in critically ill patients. Hyperferritinemia appears to be less the result of iatrogenic influences in the ICU thereby underscoring its unskewed diagnostic value.
TRIAL REGISTRATION
The study was registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016.

Identifiants

pubmed: 34252125
doi: 10.1371/journal.pone.0254345
pii: PONE-D-21-06136
pmc: PMC8274924
doi:

Substances chimiques

Ferritins 9007-73-2

Banques de données

ClinicalTrials.gov
['NCT02854943']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0254345

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Blood. 2009 Nov 19;114(21):4632-8
pubmed: 19721013
North Clin Istanb. 2015 Dec 31;2(3):189-195
pubmed: 28058366
Blood. 2015 Mar 5;125(10):1548-52
pubmed: 25573993
Transfusion. 1992 Oct;32(8):764-5
pubmed: 1412686
Crit Care. 2016 Nov 28;20(1):387
pubmed: 27890016
Blood Rev. 2009 May;23(3):95-104
pubmed: 18835072
Hepat Med. 2016 Apr 15;8:39-50
pubmed: 27186144
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Transfusion. 2019 Apr;59(4):1196-1201
pubmed: 30597563
Haematologica. 2019 Feb;104(2):e51-e53
pubmed: 30213831
Aging Clin Exp Res. 2019 Dec;31(12):1727-1734
pubmed: 30707355
N Engl J Med. 2012 Jan 26;366(4):348-59
pubmed: 22276824
Am J Clin Pathol. 2016 May;145(5):646-50
pubmed: 27247369
Nephrol Dial Transplant. 2000 Jun;15(6):883-7
pubmed: 10831646
Crit Care. 2020 May 24;24(1):244
pubmed: 32448380
Medicina (Kaunas). 2020 Feb 12;56(2):
pubmed: 32059426
Ann Hematol. 2013 Aug;92(8):1121-8
pubmed: 23604429
Patient Prefer Adherence. 2014 Apr 22;8:513-7
pubmed: 24790419
Hematology. 2018 Dec;23(10):817-822
pubmed: 29914346
Transfus Med Rev. 2015 Apr;29(2):90-101
pubmed: 25595476
Am J Med. 2018 Mar;131(3):319-322
pubmed: 29061498
Br J Haematol. 2018 May;181(3):331-340
pubmed: 29672840
Shock. 2020 Jun;53(6):701-709
pubmed: 31626037
Semin Dial. 2009 Sep-Oct;22(5):524-31
pubmed: 19558629
Crit Care Med. 2020 Apr;48(4):459-465
pubmed: 32205591
Nephrology (Carlton). 2017 Nov;22(11):838-847
pubmed: 28749067
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265

Auteurs

Cornelia Knaak (C)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Friederike S Schuster (FS)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Peter Nyvlt (P)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Patrick Heeren (P)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Claudia Spies (C)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Thomas Schenk (T)

Department of Hematology and Oncology, Universitätsklinikum Jena, Jena, Germany.

Paul La Rosée (P)

Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany.

Gritta Janka (G)

Clinic of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany.

Frank M Brunkhorst (FM)

Department of Anesthesiology and Intensive Care Medicine, Center for Clinical Studies, Universitätsklinikum Jena, Jena, Germany.

Gunnar Lachmann (G)

Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH